What Is Geroscience

Geroscience is the interdisciplinary field that investigates the biological mechanisms connecting aging to chronic disease. It operates on the premise that aging is not merely a backdrop to illness but the dominant shared risk factor for conditions such as cardiovascular disease, cancer, neurodegeneration, and metabolic syndrome. By understanding and targeting the root biological processes of aging, geroscience seeks to delay or prevent multiple diseases at once.

Most of modern medicine treats age-related diseases one at a time, after they manifest. A patient might receive a statin for cardiovascular risk, metformin for diabetes, and a cholinesterase inhibitor for cognitive decline, each targeting a single downstream condition while the underlying aging process continues to generate new pathologies. Geroscience reframes this entire approach. If aging is the upstream cause, then intervening at the level of aging biology could compress the window of late-life morbidity rather than just managing it disease by disease.

This reframing has practical consequences for how longevity is pursued. Instead of asking whether a particular supplement lowers one biomarker, geroscience asks whether an intervention modifies the fundamental trajectory of biological aging across tissues and organ systems. The field gives scientific structure to the intuition that aging itself is modifiable, and it provides a shared vocabulary and research agenda for evaluating which interventions actually matter.

Geroscience is organized around several interconnected biological processes, commonly known as the hallmarks of aging. These include genomic instability (the accumulation of DNA damage over time), telomere attrition (progressive shortening of chromosome-capping structures), epigenetic alterations (changes in gene expression patterns without changes to DNA sequence), loss of proteostasis (failure of protein folding and clearance systems), deregulated nutrient sensing (dysfunction in pathways like mTOR, AMPK, and insulin/IGF-1 signaling), mitochondrial dysfunction, cellular senescence (accumulation of damaged cells that resist death and secrete inflammatory signals), stem cell exhaustion, altered intercellular communication (including chronic low-grade inflammation), and disabled macroautophagy (reduced cellular recycling). Each hallmark does not act in isolation; they reinforce one another in feedback loops that accelerate biological aging.

The mechanistic insight that ties these hallmarks together is that they share upstream regulators and downstream consequences. For example, mitochondrial dysfunction increases oxidative stress, which contributes to DNA damage and genomic instability, which in turn triggers cellular senescence. Senescent cells secrete pro-inflammatory cytokines that alter intercellular communication, creating a systemic inflammatory state that impairs stem cell function and nutrient sensing. This interconnectedness is precisely why a single intervention targeting one node, such as mTOR inhibition with rapamycin or senescent cell clearance with senolytics, can produce benefits across multiple organ systems in animal models.

Geroscience also provides the conceptual framework for measuring biological age as distinct from chronological age. Epigenetic clocks, composite biomarker panels, and functional assessments of organ reserve all attempt to quantify where an individual sits on the aging trajectory. These tools allow researchers and clinicians to evaluate whether an intervention is actually slowing biological aging rather than merely improving a single surrogate marker.

Geroscience has a strong theoretical and preclinical foundation. Animal studies, particularly in mice, nematodes, and yeast, have demonstrated that single interventions targeting hallmarks of aging can extend both healthspan and lifespan. Caloric restriction remains the most reproduced lifespan-extending intervention across species. Rapamycin has extended lifespan in genetically heterogeneous mice even when started late in life. Senolytic drugs have cleared senescent cells and improved physical function in aged mice. Metformin has shown associations with reduced all-cause mortality in observational studies of diabetic populations, which led to the design of the TAME (Targeting Aging with Metformin) trial, a large human clinical trial intended to test whether metformin delays the onset of age-related diseases in non-diabetic older adults.

Human evidence remains more limited. Most hallmark-targeting interventions are in early-phase clinical trials or rely on surrogate endpoints like epigenetic age rather than hard clinical outcomes such as disease incidence or mortality. The interconnectedness of aging hallmarks, while theoretically compelling, also makes it difficult to isolate the contribution of any single pathway in humans. Epigenetic clock technologies are maturing but have not yet been validated as clinical-grade endpoints by regulatory agencies. The field is intellectually coherent and increasingly well-funded, but the gap between animal findings and confirmed human benefit remains substantial for most interventions.

Geroscience as a field carries no inherent risk, but interventions derived from it do. Rapamycin suppresses immune function at higher doses. Senolytics may impair wound healing or tissue homeostasis if senescent cells serve necessary short-term roles. Metformin can blunt exercise-induced mitochondrial adaptations. Caloric restriction may be harmful for individuals who are underweight, pregnant, or in periods of acute illness. Because geroscience-informed interventions often lack long-term human safety data, individuals pursuing off-label use of drugs like rapamycin or experimental senolytic protocols should do so under clinical supervision with appropriate monitoring.